Abstract
Sixty-nine patients with metastatic breast cancer (MBC) at initial diagnosis were analyzed to verify if metastatic pattern and clinical outcome are related to DNA ploidy determined by flow cytometry (FCM). Characteristics of 55 fully evaluable patients were as follows: median age: 61 years; postmenopausal: 75%; bone-only metastases (BM): 60%; extraosseous-only metastases (EM): 40%. Overall response rates (CR + PR) obtained with different chemotherapies and/or hormonal therapies were 58% and 68% for patients with BM and EM, respectively. Sixty percent of specimens resulted aneuploid, and the mean coefficient of variation of the complete series was 5.1%. In the whole group of patients DNA ploidy of primary tumor did not predict the metastatic pattern and had no influence upon response to treatment, duration of response, time to progression, and overall survival. When analyses were carried out according to metastatic pattern, those patients with BM showed similar results. However, within the group with EM, those with diploid tumors presented a significantly better survival (median 18 vs 13 months, p = .04). FCM-DNA analysis seems to identify a subgroup of patients with poor prognosis constituted by those who had aneuploid primary tumors and metastases to extraosseous sites.
| Original language | English |
|---|---|
| Pages (from-to) | 245-249 |
| Number of pages | 5 |
| Journal | American Journal of Clinical Oncology: Cancer Clinical Trials |
| Volume | 16 |
| Issue number | 3 |
| Publication status | Published - 1993 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Metastatic pattern and DNA ploidy in stage IV breast cancer at initial diagnosis : Relation to response and survival. / De Lena, M.; Romero, A.; Rabinovich, M.; Leone, B.; Vallejo, C.; Machiavelli, M.; Cuevas, M.; Rodriguez, R.; Lacava, J.; Perez, J.; Barletta, A.; Paradiso, A.
In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 16, No. 3, 1993, p. 245-249.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Metastatic pattern and DNA ploidy in stage IV breast cancer at initial diagnosis
T2 - Relation to response and survival
AU - De Lena, M.
AU - Romero, A.
AU - Rabinovich, M.
AU - Leone, B.
AU - Vallejo, C.
AU - Machiavelli, M.
AU - Cuevas, M.
AU - Rodriguez, R.
AU - Lacava, J.
AU - Perez, J.
AU - Barletta, A.
AU - Paradiso, A.
PY - 1993
Y1 - 1993
N2 - Sixty-nine patients with metastatic breast cancer (MBC) at initial diagnosis were analyzed to verify if metastatic pattern and clinical outcome are related to DNA ploidy determined by flow cytometry (FCM). Characteristics of 55 fully evaluable patients were as follows: median age: 61 years; postmenopausal: 75%; bone-only metastases (BM): 60%; extraosseous-only metastases (EM): 40%. Overall response rates (CR + PR) obtained with different chemotherapies and/or hormonal therapies were 58% and 68% for patients with BM and EM, respectively. Sixty percent of specimens resulted aneuploid, and the mean coefficient of variation of the complete series was 5.1%. In the whole group of patients DNA ploidy of primary tumor did not predict the metastatic pattern and had no influence upon response to treatment, duration of response, time to progression, and overall survival. When analyses were carried out according to metastatic pattern, those patients with BM showed similar results. However, within the group with EM, those with diploid tumors presented a significantly better survival (median 18 vs 13 months, p = .04). FCM-DNA analysis seems to identify a subgroup of patients with poor prognosis constituted by those who had aneuploid primary tumors and metastases to extraosseous sites.
AB - Sixty-nine patients with metastatic breast cancer (MBC) at initial diagnosis were analyzed to verify if metastatic pattern and clinical outcome are related to DNA ploidy determined by flow cytometry (FCM). Characteristics of 55 fully evaluable patients were as follows: median age: 61 years; postmenopausal: 75%; bone-only metastases (BM): 60%; extraosseous-only metastases (EM): 40%. Overall response rates (CR + PR) obtained with different chemotherapies and/or hormonal therapies were 58% and 68% for patients with BM and EM, respectively. Sixty percent of specimens resulted aneuploid, and the mean coefficient of variation of the complete series was 5.1%. In the whole group of patients DNA ploidy of primary tumor did not predict the metastatic pattern and had no influence upon response to treatment, duration of response, time to progression, and overall survival. When analyses were carried out according to metastatic pattern, those patients with BM showed similar results. However, within the group with EM, those with diploid tumors presented a significantly better survival (median 18 vs 13 months, p = .04). FCM-DNA analysis seems to identify a subgroup of patients with poor prognosis constituted by those who had aneuploid primary tumors and metastases to extraosseous sites.
UR - http://www.scopus.com/inward/record.url?scp=0027230157&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027230157&partnerID=8YFLogxK
M3 - Article
C2 - 8338059
AN - SCOPUS:0027230157
VL - 16
SP - 245
EP - 249
JO - American Journal of Clinical Oncology
JF - American Journal of Clinical Oncology
SN - 0277-3732
IS - 3
ER -